Application of a kind of timosaponin I in the preparation of anti-human ovarian cancer drug

A technology of timosaponin and ovarian cancer, which is applied in the field of application of timosaponin I in the preparation of anti-human ovarian cancer drugs, can solve the problems that the function and mechanism of action have yet to be studied, and timosaponin I has not been discovered yet, achieving a huge The effect of medicinal potential

Active Publication Date: 2022-01-28
NANJING MEDICAL UNIV
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Anemarrhenasaponin I (Anemarrhenasaponin I, An-I) is a compound isolated from the rhizome of Zhimu. Studies have shown that it is a potential 5-lipoxygenase (5-LOX) and cyclooxygenase- 2 (COX-2) dual-targeted inhibitors, but many functions and mechanisms of action of timosaponin I remain to be studied
Through literature search, etc., there is no relevant experimental research on the preparation of timosaponin I in the preparation of anti-human ovarian cancer drugs.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of a kind of timosaponin I in the preparation of anti-human ovarian cancer drug
  • Application of a kind of timosaponin I in the preparation of anti-human ovarian cancer drug
  • Application of a kind of timosaponin I in the preparation of anti-human ovarian cancer drug

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0024] The effects of timosaponin I and SHH pathway inhibitor GANT61 on the expression of SKOV3-related proteins in human ovarian cancer cells were determined by Western blotting.

[0025] 1. Experimental materials:

[0026] 1) Human ovarian cancer cell line SKOV3 (ATCC, USA);

[0027] 2) McCoy's5A incomplete medium (KGI, China);

[0028] 3) DMEM high glucose medium powder, GlutaMaxTM glutamine supplement, sodium pyruvate solution and 0.25% EDTA-trypsin (Gibco, USA);

[0029] 4) Fetal bovine serum FBS (Wisent, Canada);

[0030] 5) Penicillin-streptomycin-neomycin mixed antibiotic PSN and BCA protein detection kit (Thermo Fisher, USA);

[0031] 6) Rabbit anti-Gli1 polyclonal antibody (CST Company, USA);

[0032] 7) Rabbit anti-Sufu polyclonal antibody (Abcam, USA);

[0033] 8) Rabbit anti-GAPDH polyclonal antibody (Santa Crutz, USA);

[0034] 9) Horseradish peroxidase-labeled goat anti-mouse or anti-rabbit IgG (Jackson ImmunoResearch, USA);

[0035] 10) GANT61 powder (Se...

Embodiment 2

[0048] The effects of timosaponin I and SHH pathway inhibitor GANT61 on the expression of SKOV3-related mRNA in human ovarian cancer cells were determined by Real-Time PCR.

[0049] 1. Experimental materials:

[0050] 1) Human ovarian cancer cell line SKOV3 (ATCC, USA);

[0051] 2) McCoy's5A incomplete medium (KGI, China);

[0052] 3) DMEM high glucose medium powder, GlutaMaxTM glutamine supplement, sodium pyruvate solution and 0.25% EDTA-trypsin (Gibco, USA);

[0053] 4) Fetal bovine serum FBS (Wisent, Canada);

[0054] 5) Penicillin-streptomycin-neomycin mixed antibiotic PSN (Thermo Fisher Company, USA);

[0055] 6) TRIzol reagent (TaKaRa company, Japan);

[0056] 7) HiScriptⅡQ-RT SuperMix for qPCR (gDNA wiper) reverse transcription kit, AceQ qPCRSYBR Green Master Mix fluorescence quantitative PCR kit (Novizon, China);

[0057] 8) GANT61 powder (Selleck, USA) was dissolved in ethanol with a concentration of 10 mM, diluted with culture medium for experimental use;

[00...

Embodiment 3

[0075] Effects of timosaponin I and SHH pathway inhibitor GANT61 on the proliferation of human ovarian cancer cell SKOV3 by EdU proliferation assay

[0076] 1. Experimental materials:

[0077] 1) Human ovarian cancer cell line SKOV3 (ATCC, USA);

[0078] 2) McCoy's5A incomplete medium (KGI, China);

[0079] 3) DMEM high glucose medium powder, GlutaMaxTM glutamine supplement, sodium pyruvate solution and 0.25% EDTA-trypsin (Gibco, USA);

[0080] 4) Fetal bovine serum FBS (Wisent, Canada);

[0081] 5) Penicillin-streptomycin-neomycin mixed antibiotic PSN (Thermo Fisher Company, USA);

[0082] 6) EdU cell proliferation detection kit (Ribo Biotechnology, China);

[0083] 7) GANT61 powder (Selleck Company, USA) was dissolved in ethanol with a concentration of 10 mM, and diluted with culture medium for experimental use;

[0084] 8) Timosaponin powder (Nanjing University of Traditional Chinese Medicine, China) was dissolved in DMSO with a concentration of 1 mM and diluted with c...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides an application of timosaponin I in the preparation of an anti-human ovarian cancer drug, which belongs to the technical field of new medical applications of timosaponin I, wherein the molecular formula of timosaponin I is C 39 h 66 o 14 , the chemical structural formula is: timosaponin I of the present invention can effectively inhibit the expression of mRNA and protein GLI1 and SUFU of SHH signaling pathway-related target genes in human ovarian cancer cell SKOV3, and timosaponin I can effectively inhibit the expression of SKOV3 cells Proliferation, epithelial-mesenchymal transformation (Epithelial-mesenchymal transformation, EMT), migration and invasion, show that timosaponin I of the present invention is expected to be developed as an active ingredient of anti-human ovarian cancer drugs; According to the needs of patients, it can be made into different preparation forms, which is convenient for patients to take, and has good development and application prospects.

Description

technical field [0001] The invention belongs to the technical field of new medicinal uses of timosaponin I, in particular to the application of timosaponin I in the preparation of anti-human ovarian cancer drugs. Background technique [0002] Ovarian cancer is the most common malignancy in women over the age of 40, second only to breast cancer and the deadliest gynecological cancer. According to the 2020 survey, there are approximately 313,959 new cases of ovarian cancer and 207,252 deaths worldwide each year. Owing to the hidden location of the ovaries and the lack of effective screening methods, the vast majority of ovarian cancers have already metastasized at the time of diagnosis. At present, the treatment mode of ovarian cancer is mainly cytoreductive surgery and chemotherapy based on platinum drugs. Ovarian cancer patients often go through a cycle of surgery-chemotherapy-relapse-chemotherapy-re-relapse-re-chemotherapy, during which chemotherapy sensitivity gradually d...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/7048A61P35/00A61P15/08A61K36/8964
CPCA61K31/7048A61P35/00A61P15/08A61K36/8964
Inventor 邓斯敏刘晨许元高彬斌张静怡俞婷婷乐珅程雁
Owner NANJING MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap